Consistent with the above, the results from the IMMUNOTARGET registry, which included patients with oncogene-driven NSCLC who received immunotherapy, showed that ICI monotherapy yielded a short median PFS of 2.1 months and a low ORR of 12% among patients with NSCLC harboring EGFR alterations [108]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.